TechNavios analysts forecast the Global Kidney Cancer Drugs market to grow at a CAGR of 13.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand in developing economies. The Global Kidney Cancer Drugs market has also been witnessing an increase in R&D activities. However, over-dependence of the market on the US could pose a challenge to the growth of this market.
TechNavios report, Global Kidney Cancer Drugs Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Kidney Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are AVEO Pharmaceuticals Inc., Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc.
The other vendors mentioned in the report are AstraZeneca plc, Onyx Pharmaceuticals Inc., Merck Serono S.A., and WILEX AG
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of each of these key vendors?
01. Executive Summary
03. Market Coverage
04. Market Landscape
04.1 Market Size
04.2 Market Forecast
04.3 Market Segmentation
04.4 Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and Their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 AVEO Pharmaceuticals Inc.
15.2 Bayer AG
15.3 GlaxoSmithKline plc
15.4 Hoffmann-La Roche Ltd.
15.5 Novartis AG
15.6 Pfizer Inc.
16. Other Reports in this Series
List of Exhibits
Exhibit 1: Global Kidney Cancer Drugs Market 2012â2016 (US$ billion)
Exhibit 2: Kidney Cancer by Category Segmentation
Exhibit 3: Global Kidney Cancer Drugs Market by Category Segmentation 2012
Exhibit 4: Global Kidney Cancer Drugs Market by Geographical Segmentation 2012
Exhibit 5: Global Kidney Cancer Drugs Market by Vendor Segmentation 2012
Exhibit 6: Business Segmentation of AVEO Pharmaceuticals Inc.
Exhibit 7: Business Segmentation of Bayer AG
Exhibit 8: Business Segmentation of GlaxoSmithKline plc
Exhibit 9: Business Segmentation of Hoffmann-La Roche Ltd.
Exhibit 10: Business Segmentation of Novartis AG
Exhibit 11: Business Segmentation of Pfizer Inc.